MAOB and Parkinson disease: The compounds were tested for antagonistic potency at all four ARs as well as for inhibitory potency at both MAO enzymes with the goal to improve potency at A1 and A2A ARs and MAO-B, which are (potential) targets for the treatment of neurodegenerative diseases, in particular for PD.